Skip to Main Content

DC

Animal-origin-free proteins for every step of Dendritic Cell manufacturing.

From leukapheresis to cryopreservation, recombinant albumin, transferrin, and insulin-transferrin supplements replace serum and plasma-derived albumin, lowering the variability serum brings into monocyte and dendritic cell culture.

Where InVitria proteins fit in Dendritic Cell Manufacturing

Dendritic cell therapy runs from a leukapheresis product through monocyte isolation, several days of differentiation, antigen loading, maturation, washing, formulation and freezing, with albumin in the buffer or medium at every step. Human serum, fetal bovine serum, bovine serum albumin and plasma-derived albumin bring variability, animal-origin material and adventitious agent risk into each of them. Defined, animal-origin-free recombinant albumin, transferrin and insulin-transferrin supplements take their place, step by step.

Where our products fit

The dendritic cell workflow, step by step.

Explore where our animal-origin-free supplements fit at each step of DC manufacturing.

Starting Material & Cell Source

Procure the patient or donor leukapheresis product as the source of monocytes, and protect the cells during collection and transport with defined, animal-origin-free albumin.

Overview

Starting material and cell source is the first step in dendritic cell therapy. Most dendritic cell vaccines are autologous, made from the patient’s own white blood cells. The starting material is a leukapheresis product, collected by apheresis to concentrate mononuclear cells, including the monocytes that will become dendritic cells. Some allogeneic and donor-derived approaches also exist.

The leukapheresis product is collected and transported to the manufacturing site before monocyte isolation. Handling, time, and temperature between collection and processing affect cell viability and the quality of the monocytes recovered.

Protecting the cells during this early window supports recovery and a consistent starting point, and a defined, animal-origin-free stabilizing protein avoids introducing serum- or animal-derived material at the start.

Functions

Starting Material Stabilization

Dendritic cell therapy starts from a patient or donor leukapheresis product. Between collection and processing, the cells are exposed to temperature shifts, handling, and surface contact. Cell viability at this stage affects the yield and quality of monocytes recovered for differentiation. A stabilizing protein supports cell health through transport and hold, before isolation begins.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Commonly replaces
Serum or plasma-derived albumin used to stabilize collected apheresis cells.

Monocyte Isolation & Washing

Isolate CD14+ monocytes from the leukapheresis product by selection or adherence, and wash them into culture medium with defined, animal-origin-free albumin.

Overview

Monocyte isolation recovers the CD14+ monocytes that will be differentiated into dendritic cells. Monocytes are commonly enriched by immunomagnetic CD14 selection in a closed system, by counterflow elutriation, or by density-gradient separation followed by plate adherence. The isolated monocytes are washed and resuspended in culture medium.

Isolation and washing expose cells to selection reagents, centrifugation, and buffer exchange. In some workflows the monocytes are cryopreserved at this stage for later culture, using an albumin-based freezing medium. Albumin is commonly included in isolation, wash, and freezing solutions to protect cells.

A defined, animal-origin-free recombinant albumin protects monocytes through isolation and washing while keeping the process free of serum-derived material.

Functions

Cell Protection & Stabilization

During isolation, monocytes are enriched by CD14 selection, elutriation, or adherence, then washed, which exposes them to selection reagents, centrifugation, and buffer exchange. Albumin supports viability by transporting fatty acids and binding reactive species, buffering cells against handling and oxidative stress as they move into culture or cryopreservation.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Commonly replaces
Serum or bovine serum albumin (BSA) in monocyte isolation and freezing media.

Monocyte-to-Dendritic Cell Differentiation

Differentiate monocytes into immature dendritic cells with GM-CSF and IL-4 over several days, on a defined, animal-origin-free serum-free base.

Overview

Differentiation converts the isolated monocytes into immature dendritic cells. Monocytes are cultured for roughly five to seven days in the presence of GM-CSF and IL-4, the cytokines that drive monocyte-to-dendritic-cell differentiation. The result is immature dendritic cells with high antigen-uptake capacity.

GM-CSF and IL-4 are the active differentiation factors and are supplied separately; they are not InVitria products. Modern protocols run under serum-free conditions, where a defined protein base, albumin, transferrin, and metabolic components, replaces the human serum or FBS used in older methods. This base supports cell health while the cytokines drive differentiation.

Maintaining defined, animal-origin-free conditions supports consistent differentiation and reduces the variability and animal-origin risk that serum introduces. InVitria components supply the defined protein and metabolic base of serum-free dendritic cell media.

Monocytes are differentiated to immature dendritic cells with GM-CSF and IL-4 over several days.

Functions

Iron Transport

Differentiating monocytes require iron for metabolism and proliferation through the differentiation window. In serum-free dendritic cell media, transferrin delivers iron in a controlled, protein-bound form through the transferrin receptor, supporting cell health while limiting the oxidative stress associated with free iron. Transferrin is a standard component of serum-free media for myeloid-lineage cells.

Recommendation
Optiferrin®

Recombinant human transferrin, lyophilized, for iron delivery in serum-free and chemically defined media.

Commonly replaces
Serum- or plasma-derived transferrin in serum-free dendritic cell media.

Carrier & Protection

Albumin is the primary protein carrier in serum-free dendritic cell media. It binds and transports fatty acids, lipids, and metal ions, contributes antioxidant capacity, and buffers cells against handling stress through the multi-day differentiation culture. This carrier and protective role supports cell viability and consistent differentiation.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Commonly replaces
Human serum, human serum albumin (HSA), or bovine serum albumin (BSA) in DC media.

Serum-Free Environment Support

Serum-free differentiation depends on a defined metabolic base, insulin for metabolism, transferrin for iron, and selenium for oxidative balance, in place of human serum or FBS. A blend supplies these in one addition, supporting monocyte health and consistent differentiation while GM-CSF and IL-4 drive the process separately.

Recommendation
ITSE+A Animal-Free®

Five-component 100x supplement of recombinant insulin, recombinant human transferrin, selenium, ethanolamine, and recombinant human albumin for serum-free cell culture.

Commonly replaces
Human serum or FBS in monocyte-to-dendritic-cell differentiation media.

Antigen Loading

Load immature dendritic cells with tumor antigen, by lysate, peptide, mRNA, or viral vector, with defined, animal-origin-free albumin protecting cells during loading.

Overview

Antigen loading gives the dendritic cells the tumor antigen they will present to the immune system. Immature dendritic cells are pulsed with antigen in one of several forms: tumor lysate, defined peptides, messenger RNA, or a viral vector encoding a tumor-associated antigen. A carrier protein such as KLH is sometimes co-loaded.

The antigen source is the active material of this step and is selected for the specific therapy; it is not an InVitria product. During loading, cells continue in culture and remain sensitive to handling and oxidative stress.

A defined, animal-origin-free recombinant albumin protects cells through the loading step while keeping the process free of serum-derived material ahead of maturation.

Functions

Cell Protection & Stabilization

During antigen loading, immature dendritic cells are pulsed with antigen and continue in culture, which exposes them to handling and the metabolic demands of antigen uptake and processing. Albumin supports viability by transporting fatty acids and binding reactive species, buffering cells against oxidative stress through the loading window.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Commonly replaces
Serum or bovine serum albumin (BSA) in antigen-loading media.

Cell Maturation & Activation

Mature the antigen-loaded dendritic cells with a pro-inflammatory cytokine cocktail, on a defined, animal-origin-free albumin base, into a potent T-cell-stimulating product.

Overview

Maturation and activation converts the antigen-loaded immature cells into mature dendritic cells able to migrate to lymph nodes and prime T cells. Maturation is induced over one to two days with a pro-inflammatory cocktail. The gold-standard cocktail combines TNF-alpha, IL-1-beta, IL-6, and PGE2; some protocols add IFN-gamma or Toll-like receptor ligands to boost potency.

These maturation cytokines and ligands are the active agents of the step and are supplied separately; they are not InVitria products. Maturation determines the final phenotype and potency of the product, including expression of the lymph-node homing receptor CCR7. The cells remain in a defined serum-free medium during maturation.

A defined, animal-origin-free recombinant albumin supports cell viability through maturation while keeping the product free of serum-derived material ahead of washing and formulation.

Maturation uses a defined cytokine/agonist cocktail (e.g., TNF-alpha, IL-1beta, IL-6, and PGE2, or TLR agonists) to drive the mature, migratory, T-cell-stimulatory phenotype.

Functions

Carrier & Protection

During maturation, dendritic cells respond to a pro-inflammatory cocktail over one to two days while remaining in serum-free culture. Albumin is the primary protein carrier in this medium, binding and transporting fatty acids, lipids, and metal ions, contributing antioxidant capacity, and buffering cells against handling stress as they acquire the mature phenotype.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Commonly replaces
Human serum, human serum albumin (HSA), or bovine serum albumin (BSA) in maturation media.

Cell or Component Washing

Wash the mature dendritic cells to remove cytokines, antigen residuals, and spent media, with defined, animal-origin-free albumin protecting cells through the step.

Overview

Cell or component washing removes process residuals from the mature dendritic cells before formulation. The cells are washed to clear maturation cytokines, residual antigen and loading reagents, and spent media, leaving a clean product for final formulation.

Washing exposes cells to repeated centrifugation and buffer exchange. Wash buffers commonly contain albumin to protect cells and limit loss during these steps.

A defined, animal-origin-free recombinant albumin protects cells through washing and buffer exchange while avoiding animal-derived residuals ahead of final formulation.

Functions

Cell Protection & Stabilization

During washing, mature dendritic cells are exposed to repeated centrifugation and buffer exchange to remove cytokines and process residuals. Albumin protects cells by transporting fatty acids and binding reactive species, buffering them against handling and oxidative stress and limiting loss to surfaces through the step.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Commonly replaces
Serum or bovine serum albumin (BSA) in dendritic cell wash buffers.

Final Formulation & Fill Prep

Formulate the mature dendritic cells into their final matrix with defined, animal-origin-free recombinant albumin, a drug-product excipient that stabilizes the vaccine for fill.

Overview

Final formulation and fill prep brings the dendritic cell vaccine to its finished form. The washed, mature cells are suspended in the matrix they will be stored and administered in, then filled into the primary container. Depending on the product, the vaccine is administered fresh or cryopreserved for dosing over time.

Albumin is a standard excipient in cell-therapy formulation and freezing matrices. It stabilizes the cells through formulation and into freezing. Because this is the drug product, excipient safety matters: plasma-derived albumin carries adventitious-agent risk that a recombinant source removes.

A defined, animal-origin-free recombinant albumin stabilizes the formulated vaccine while keeping the final matrix free of human- and animal-derived material as it goes to fill.

Functions

Formulation Stabilization

In final formulation, the mature cells are suspended in the matrix they will be stored and administered in. Albumin is a standard excipient in this matrix. It stabilizes cells, buffers them against the osmotic and handling stress of formulation and the hold before freezing, and limits adsorption to the container. As a drug-product excipient, its quality and safety profile carry into the final vaccine.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Commonly replaces
Plasma-derived human serum albumin (HSA) used as a formulation excipient.

Cryopreservation & Storage

Freeze and store the dendritic cell vaccine, with defined, animal-origin-free albumin supporting cell stability and potency through freeze-thaw and recovery.

Overview

Cryopreservation and storage freezes and banks the finished vaccine, enabling multiple doses from a single manufacturing run and dosing over a course of treatment. The formulated cells are cooled in a controlled-rate freezer and held in cryogenic storage, then thawed before administration.

Freeze-thaw exposes cells to ice formation and osmotic stress, and mature dendritic cells must retain viability and their mature, T-cell-stimulating phenotype after thaw. Cryopreservation matrices for dendritic cells commonly pair DMSO with a high concentration of human serum albumin, which protects the cells through freezing.

A defined, animal-origin-free recombinant albumin supports cryostability and recovery while keeping the frozen vaccine free of human- and animal-derived material.

Functions

Freeze-Thaw Stabilization

Cryopreservation exposes cells to ice crystal formation, osmotic shifts, and membrane stress during freezing and thawing, and dendritic cells must retain both viability and their mature phenotype on thaw. Dendritic cell freezing matrices pair a penetrating cryoprotectant such as DMSO with a high concentration of albumin. Albumin acts as the non-penetrating stabilizer, buffering membranes against osmotic and oxidative stress and supporting recovery after thaw.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Commonly replaces
Plasma-derived human serum albumin (HSA) used as a cryopreservation stabilizer.